Which post-marketing database and studies does EMEA require
Gottfried Kreutz, Leng HengFederal Institute
for Drugs and Medical Devices, Department Clinical Pharmacology I,
Friedrich-Ebert-Allee 38, D-53113 Bonn, Germany
Correspondence to: Dr Kreutz
| The first 150 words of the full text of this article appear below. |
| |
Article |
|---|
The European process for assessment of pharmaceutical products is complex and presents with different levels. There is the European level with two major procedures resulting in decisions on approval after applications to market a pharmaceutical product in European countries. One is the centralised procedure organised by the European Medicines Evaluation Agency (EMEA). The other one is the mutual recognition procedure performed by consensus between Member States. The decisive body on the European level for medicines for humans is the Committee for Proprietary Medicinal Products (CPMP) with representation of two members from each of the countries of the European Union. This expert body is supported by others (Working Parties) where specialist competence within each of the areas and from each of the member states is providing ample opportunities for exchange of expertise and consensus discussions (fig 1).
| Figure Removed (Available Only in the Full Text) |
Medical regulatory requirements including clinical efficacy and
clinical safety aspects are discussed and
Register for free content
The full back archive is now available for all BMJ Journals. Institutional subscribers may access the entire archive as part of their subscription. Personal subscribers will also have access to all content when logged in. Non-subscribers who register have free access to all articles published before 2006 right back to volume 1 issue 1. Register here to access the free archive of all BMJ Journals.
Don't forget to sign up for content alerts so you keep up to date with all the articles as they are published.
